P3 Health Partners Inc. (PIII) Financial Ratios
6 years of historical data (2019–2024) · Healthcare · Medical - Care Facilities
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
0.07
↓-66% vs avg
5yr avg: 0.20
30Y Low0.1·High0.3
ROE
↓
-46.6%
↑-95% vs avg
5yr avg: -23.9%
30Y Low-47%·High-12%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
PIII Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
P3 Health Partners Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Market Cap | $11M | $33M | $134M | $77M | $293M | — | — |
| Enterprise Value | $138M | $160M | $222M | $166M | $244M | — | — |
| P/E Ratio → | -0.07 | — | — | — | — | — | — |
| P/S Ratio | 0.01 | 0.02 | 0.11 | 0.07 | 0.46 | — | — |
| P/B Ratio | 0.07 | 0.22 | 0.31 | 0.15 | 0.14 | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
PIII EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.11 | 0.18 | 0.16 | 0.38 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
PIII Profitability
Margins and return-on-capital ratios measuring operating efficiency
P3 Health Partners Inc. earns an operating margin of -21.4%. Operating margins have expanded from -148.7% to -21.4% over the past 3 years, signaling improving operational efficiency. A negative ROE of -46.6% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | -4.8% | 100.0% | 100.0% |
| Operating Margin | -21.4% | -21.4% | -13.3% | -148.7% | -29.5% | -5.8% | -27.2% |
| Net Profit Margin | -9.1% | -9.1% | -4.6% | -25.7% | -24.6% | -6.4% | -28.8% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| ROE | -46.6% | -46.6% | -12.1% | -20.9% | -16.2% | — | — |
| ROA | -16.5% | -16.5% | -6.6% | -16.7% | -12.7% | -36.5% | -64.0% |
| ROIC | -60.2% | -60.2% | -22.2% | -89.1% | -14.8% | — | — |
| ROCE | -75.6% | -75.6% | -28.1% | -111.5% | -17.2% | -212.9% | -358.4% |
PIII Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $127M ($166M total debt minus $39M cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.11 | 1.11 | 0.29 | 0.21 | 0.04 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.85 | 0.20 | 0.17 | -0.02 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | -14.46 | -14.46 | -10.51 | -136.87 | -17.61 | -11.29 | -15.60 |
PIII Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.37x is below 1.0, meaning current liabilities exceed current assets.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 0.37 | 0.37 | 0.55 | 0.42 | 1.01 | 1.00 | 0.96 |
| Quick Ratio | 0.37 | 0.37 | 0.55 | 0.42 | 1.01 | 1.00 | 0.96 |
| Cash Ratio | 0.08 | 0.08 | 0.12 | 0.08 | 0.71 | 0.40 | 0.60 |
| Asset Turnover | — | 1.92 | 1.47 | 1.20 | 0.27 | 4.61 | 2.22 |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 30.46 | 35.01 | 27.68 | 29.40 | 33.92 | 45.08 |
PIII Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
P3 Health Partners Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $3M | $2M | $831580 | $831577 | $790625 | $475880 |
Peer Comparison
Compare PIII with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 PIIIYou | $11M | -0.1 | — | — | 100.0% | -21.4% | -46.6% | -60.2% | — |
 AGIO | $2B | -3.9 | — | — | 78.7% | -873.9% | -30.2% | -26.3% | — |
 ALHC | $4B | -4932.4 | 77.1 | 33.0 | 12.4% | 0.4% | -0.5% | — | 7.5 |
 OSCR | $5B | -12.3 | — | 5.1 | 14.4% | -3.4% | -44.4% | — | — |
 CNC | $27B | -4.0 | — | 6.3 | 12.2% | -3.9% | -28.7% | -21.6% | — |
 MOH | $10B | 21.5 | 9.9 | — | 9.0% | 1.7% | 11.0% | 17.4% | 4.0 |
 CVS | $111B | 62.8 | 13.1 | 14.3 | 13.8% | 2.6% | 2.3% | 5.0% | 6.2 |
 HUM | $30B | 25.1 | 16.9 | 79.1 | 14.5% | 1.1% | 7.0% | 4.1% | 5.7 |
 CLOV | $1B | -16.6 | — | — | 18.5% | -4.4% | -26.3% | -34.0% | — |
 UNH | $336B | 27.9 | 16.7 | 20.9 | 18.5% | 4.2% | 11.8% | 9.2% | 3.4 |
 TDOC | $1B | -6.1 | 15.1 | 4.4 | 69.5% | -10.4% | -13.9% | -11.5% | 10.4 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 6 years · Updated daily
See PIII's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PIII Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PIII vs AGIO
Side-by-side business, growth, and profitability comparison vs Agios Pharmaceuticals, Inc..
Start ComparisonPIII — Frequently Asked Questions
Quick answers to the most common questions about buying PIII stock.
What is P3 Health Partners Inc.'s P/E ratio?
P3 Health Partners Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
What is P3 Health Partners Inc.'s ROE?
P3 Health Partners Inc.'s return on equity (ROE) is -46.6%. The historical average is -23.9%.
Is PIII stock overvalued?
Based on historical data, P3 Health Partners Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are P3 Health Partners Inc.'s profit margins?
P3 Health Partners Inc. has 100.0% gross margin and -21.4% operating margin.